Michal Rose, MD
ProfessorDownloadHi-Res Photo
Cards
Appointments
Medical Oncology and Hematology
Primary
Additional Titles
Director, VA Comprehensive Cancer Center
Chief, Veterans Affairs
Contact Info
Appointments
Medical Oncology and Hematology
Primary
Additional Titles
Director, VA Comprehensive Cancer Center
Chief, Veterans Affairs
Contact Info
Appointments
Medical Oncology and Hematology
Primary
Additional Titles
Director, VA Comprehensive Cancer Center
Chief, Veterans Affairs
Contact Info
About
Copy Link
Titles
Professor
Director, VA Comprehensive Cancer Center; Chief, Veterans Affairs
Appointments
Medical Oncology and Hematology
ProfessorPrimary
Other Departments & Organizations
- Cancer Prevention and Control
- Developmental Therapeutics
- Internal Medicine
- Medical Oncology and Hematology
- Yale Cancer Center
- Yale Ventures
Education & Training
- MD
- Hebrew University (1987)
Research
Copy Link
Overview
Medical Research Interests
Health Services Research; Hematology; Medical Oncology; Veterans
Public Health Interests
Health Care Management
Research at a Glance
Yale Co-Authors
Frequent collaborators of Michal Rose's published research.
Publications Timeline
A big-picture view of Michal Rose's research output by year.
Research Interests
Research topics Michal Rose is interested in exploring.
Tamar Taddei, MD
Amer Zeidan, MBBS, MD
David Su, MD
Herta Chao, MD, PhD
Hilary Cain, MD
Ifeyinwa Onyiuke, MBBS
11Publications
562Citations
Medical Oncology
Publications
2025
Heterogeneous Tumor Profiles in Hepatocellular Carcinoma: An Example of Late Recurrences With Genetically Distinct Tumors Over a 10-Year Survival
Cao Y, Laurans M, Onyiuke I, Walther Z, Zhang X, Rose M, Taddei T. Heterogeneous Tumor Profiles in Hepatocellular Carcinoma: An Example of Late Recurrences With Genetically Distinct Tumors Over a 10-Year Survival. ACG Case Reports Journal 2025, 12: e01670. DOI: 10.14309/crj.0000000000001670.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaTumor profilingLate recurrenceNext-generation sequencingRuptured hepatocellular carcinomaMetastasis 3 yearsDistinct tumorsProlonged survivalGenetically distinct tumorsRecurrenceUnique caseTargeted mutationCarcinomaTumorClinical insightsSurvivalPresentationGenetic sequencesPatientsThe Association Between Sex and Lung Cancer Screening Adherence to Follow-Up in a Cohort of Veterans
Bernstein E, Bade B, DeRycke E, Lerz K, Zeghlache R, Rose M, Kravetz J, Farmer M, Bastian L, Akgün K, Cain H. The Association Between Sex and Lung Cancer Screening Adherence to Follow-Up in a Cohort of Veterans. Journal Of Women's Health 2025, 34: 601-605. PMID: 40045919, DOI: 10.1089/jwh.2024.0780.Peer-Reviewed Original ResearchCitationsAltmetricConceptsLung cancer screeningFemale veteransLung-RADSRates of nonadherencePrimary careUnited States Preventive Services Task Force guidelinesAdherence to lung cancer screeningCancer Screening AdherenceLung-RADS 1Lung-RADS scoreLung-RADS 3Associated with greater nonadherenceTask Force guidelinesCohort of veteransFollow-upFollow-up recommendationsLogistic regression modelsScreening adherenceCancer screeningReduce disparitiesForce guidelinesRetrospective cohort studySubstance use disordersSocioeconomic statusScreening program
2024
Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations
Jayakrishnan R, Kwiatkowski D, Rose M, Nassar A. Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations. The Oncologist 2024, 29: 833-841. PMID: 38907669, PMCID: PMC11449018, DOI: 10.1093/oncolo/oyae091.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricConceptsMutational signaturesNon-small cell lung cancerBase substitutionsNon-small lung cancerCell lung cancerLung cancerSingle base substitutionsDoublet base substitutionsResponse to personalized treatmentGenomics effortsMutational signature analysisGenesis of cancerLoss of mismatch repairResponse to therapyMutational processesDamaged DNAAPOBEC activityMismatch repairRepair mechanismsTumor evolutionEndogenous processesMutationsPersonalized treatmentCancerTobacco smokeOutcomes Following Implementation of an Electronic Model for Perioperative Hematologic Consultation
Su D, Rehman S, Wang K, Deng Y, Rose M, Dosani T, Kunstman J. Outcomes Following Implementation of an Electronic Model for Perioperative Hematologic Consultation. Journal Of Surgical Research 2024, 301: 10-17. PMID: 38905768, DOI: 10.1016/j.jss.2024.04.033.Peer-Reviewed Original ResearchCitationsAltmetricConceptsHematology consultationSingle-center retrospective studyClavien-Dindo classificationVA Connecticut Healthcare SystemAssess operative outcomesTime to resolutionPrimary outcome measureE-consultationOperative morbidityPostoperative transfusionHematologic complicationsSurgical outcomesNo significant differenceRetrospective studyProcedural dataOperative outcomesProcedural outcomesStudy cohortPatient characteristicsConsult volumeSecondary outcomesHematologic issuesAssociated with changesReferral patternsSurgerySystemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights
Rose M, Kennedy E, Abou-Alfa G, Finn R, Gade T, Kelley R, Taddei T, Gordan J. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights. JCO Oncology Practice 2024, 20: 1035-1039. PMID: 38662970, DOI: 10.1200/op.24.00189.Peer-Reviewed Original ResearchCitationsAltmetricSystemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
Gordan J, Kennedy E, Abou-Alfa G, Beal E, Finn R, Gade T, Goff L, Gupta S, Guy J, Hoang H, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb A, Kelley R, Kortmansky J, Leaf A, Remak W, Sohal D, Taddei T, Wilson Woods A, Yarchoan M, Rose M. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. Journal Of Clinical Oncology 2024, 42: 1830-1850. PMID: 38502889, DOI: 10.1200/jco.23.02745.Peer-Reviewed Original ResearchCitationsAltmetricConceptsTyrosine kinase inhibitorsAdvanced hepatocellular carcinomaSecond-line therapyFirst-line treatmentRandomized Controlled TrialsHepatocellular carcinomaSystemic therapyFirst-lineChild-Pugh class A liver diseaseEastern Cooperative Oncology Group performance status 0Child-Pugh class A patientsSecond-line therapy optionsFirst-line settingPerformance status 0Third-line therapyFirst-line therapyClass A patientsEvidence-based guidelinesTolerated sorafenibStatus 0A patientsMechanism of actionTherapy optionsClinical decision-makingGuideline update
2023
Myelodysplastic Syndromes/Neoplasms—Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and Treatments
Rose M, Zeidan A. Myelodysplastic Syndromes/Neoplasms—Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and Treatments. The Cancer Journal 2023, 29: 109-110. PMID: 37195765, DOI: 10.1097/ppo.0000000000000663.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAltmetricMeSH Keywords and Concepts
2020
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Deininger M, Shah N, Altman J, Berman E, Bhatia R, Bhatnagar B, DeAngelo D, Gotlib J, Hobbs G, Maness L, Mead M, Metheny L, Mohan S, Moore J, Naqvi K, Oehler V, Pallera A, Patnaik M, Pratz K, Pusic I, Rose M, Smith B, Snyder D, Sweet K, Talpaz M, Thompson J, Yang D, Gregory K, Sundar H. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2020, 18: 1385-1415. PMID: 33022644, DOI: 10.6004/jnccn.2020.0047.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
2010
Prostate Cancer, Comorbidity, and Participation in Randomized Controlled Trials of Therapy
Chao H, Mayer T, Concato J, Rose M, Uchio E, Kelly K. Prostate Cancer, Comorbidity, and Participation in Randomized Controlled Trials of Therapy. Journal Of Investigative Medicine 2010, 58: 566-568. DOI: 10.2310/jim.0b013e3181cf9002.Peer-Reviewed Original ResearchCitationsConceptsCastrate-resistant prostate cancerPhase 3 RCTsProstate cancerClinical settingPhase 3 clinical trialsVeterans Affairs Connecticut Healthcare SystemGeneral oncology practiceAbnormal laboratory valuesPopulation of patientsRandomized Controlled TrialsComplete medical recordsSerious medical conditionProportion of menBackground RandomizedChemotherapy regimensCRPC patientsControlled TrialsMedical recordsClinical trialsOncology practiceInclusion criteriaLaboratory valuesCardiac diseaseMedical conditionsClinical careChapter 49 Disorders of Red Blood Cells
Rose M, Berliner N. Chapter 49 Disorders of Red Blood Cells. 2010, 520-532. DOI: 10.1016/b978-1-4160-6109-0.00049-6.BooksCitations
News
Copy Link
Get In Touch
Copy Link